Trends in the days of cefalexin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in the days of quinolone therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in the length of hospital stay by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

Subjects:

Trends in the days of macrolides therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in the days of amoxicillin and amoxicillin-clavulanate therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in the days of third-generation cephalosporin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Subjects:

Trends in the incidence of <i>Clostridioides difficile</i> infection (CDI) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phas... by Naoya Itoh (6029276)

Subjects:

Trends in the incidence of extended-spectrum β-lactamase (ESBL)- producing Enterobacteriaceae per 1000 patients, by month, during the pre-intervention period (Phase 1) and interven... by Naoya Itoh (6029276)

Subjects:

Trends in the incidence of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional pe... by Naoya Itoh (6029276)

Subjects:

Trends in the incidence of penicillin-resistant <i>Streptococcus pneumoniae</i> (PRSP) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional... by Naoya Itoh (6029276)

Subjects:

Trends in the incidence of resistant <i>Haemophilus influenzae</i> per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).... by Naoya Itoh (6029276)

Subjects:

Total and resource-specific absolute costs (in 2020 CAD) per quarter in 2020 and percentage change from 2018 and 2019 for all individuals in Ontario. by Seraphine Zeitouny (16954499)

Subjects:

Ratio of firmicutes/bacteroidetes changes in F2 samples with sulfite treatments at time 0. by Sally V. Irwin (4521733)

Subjects:

Performances of the three machine learning models based on ten-fold cross-validation and walk-forward validation: Multiple linear regression (MLR), random forest (RF), and a deep n... by Yingjie Hu (1579000)

Subjects:

Changes in the 12 gastrointestinal symptoms based on the FSSG scores from 2010 to 2019 among generally healthy individuals in Japan. by Nobutake Yamamichi (381131)

Eight urinary metabolites exhibited significant changes in the MSG-treated groups at week 12, and MSG-withdrawal group at weeks 0, 4, 8, 10, and 12. by Manatsaphon Sukmak (19532771)

Total and resource-specific absolute costs per quarter in 2020 (in 2020 CAD) and percentage change from 2018 and 2019 for all individuals in British Columbia. by Seraphine Zeitouny (16954499)

Subjects:

Changes in treatment for opioid use disorder. by Claire So Jeong Lee (19507862)

“…There were no statistically significant differences in the rates of decrease in receptive sharing of injection equipment or in the percentage of participants receiving treatment for opioid use disorders in the two arms.…”

Number of significant genes and fold change. by Gordon A. Barr (11163243)

Significant main effect of age showing decreased gray matter volume in nearly the entire cortical brain and subcortical cortex. by Zhiliang Long (306092)